Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial

Authors :: Paul W. Jones
David A. Lipson
Edward Kerwin
Leif Bjermer
Chris Compton
Lee Tombs
Claus Vogelmeier
Isabelle Boucot
François Maltais
Source :: Airway pharmacology and treatment.
Publication Year :: 2021
Publisher :: European Respiratory Society, 2021.

Subjects :: medicine.medical_specialty
UMECLIDINIUM/VILANTEROL
business.industry
Internal medicine
Post-hoc analysis
medicine
Cardiology
business
Lung function

Full Text Access

Tools